Your browser doesn't support javascript.
loading
Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension / 医学前沿
Frontiers of Medicine ; (4): 102-110, 2022.
Article in English | WPRIM (Western Pacific) | ID: wpr-929186
Responsible library: WPRO
ABSTRACT
Consecutively hospitalized patients with confirmed coronavirus disease 2019 (COVID-19) in Wuhan, China were retrospectively enrolled from January 2020 to March 2020 to investigate the association between the use of renin-angiotensin system inhibitor (RAS-I) and the outcome of this disease. Associations between the use of RAS-I (angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB)), ACEI, and ARB and in-hospital mortality were analyzed using multivariate Cox proportional hazards regression models in overall and subgroup of hypertension status. A total of 2771 patients with COVID-19 were included, with moderate and severe cases accounting for 45.0% and 36.5%, respectively. A total of 195 (7.0%) patients died. RAS-I (hazard ratio (HR)= 0.499, 95% confidence interval (CI) 0.325-0.767) and ARB (HR = 0.410, 95% CI 0.240-0.700) use was associated with a reduced risk of all-cause mortality among patients with COVID-19. For patients with hypertension, RAS-I and ARB applications were also associated with a reduced risk of mortality with HR of 0.352 (95% CI 0.162-0.764) and 0.279 (95% CI 0.115-0.677), respectively. RAS-I exhibited protective effects on the survival outcome of COVID-19. ARB use was associated with a reduced risk of all-cause mortality among patients with COVID-19.
Subject(s)

Full text: Available Health context: SDG3 - Target 3.3 End transmission of communicable diseases / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: COVID-19 / Pneumonia / Arterial Hypertension / Cardiovascular Disease / Other Respiratory Diseases Database: WPRIM (Western Pacific) Main subject: Renin-Angiotensin System / Angiotensin-Converting Enzyme Inhibitors / Retrospective Studies / Angiotensin Receptor Antagonists / COVID-19 / Hypertension Type of study: Etiology study / Observational study / Risk factors Limits: Humans Language: English Journal: Frontiers of Medicine Year: 2022 Document type: Article
Full text: Available Health context: SDG3 - Target 3.3 End transmission of communicable diseases / SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: COVID-19 / Pneumonia / Arterial Hypertension / Cardiovascular Disease / Other Respiratory Diseases Database: WPRIM (Western Pacific) Main subject: Renin-Angiotensin System / Angiotensin-Converting Enzyme Inhibitors / Retrospective Studies / Angiotensin Receptor Antagonists / COVID-19 / Hypertension Type of study: Etiology study / Observational study / Risk factors Limits: Humans Language: English Journal: Frontiers of Medicine Year: 2022 Document type: Article
...